An observational study in Gastric Cancer, Chemotherapy Effect and Predictive Cancer Model, sponsored by Kyungpook National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-04.
Sponsored by Kyungpook National University Hospital · Observational
Among 521 studies in Stomach Neoplasms with a site in Korea, Republic of — 78 open to participants now, 116 under way, 20 of them phase 3. Stomach Neoplasms · Korea, Republic of.
Among the 521 studies in Stomach Neoplasms with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 71 observational ones that give a count, is one of 29 that started in 2015, is one of 71 observational ones, reaches primary completion later than 14 of the 115 other live ones, and was the 286th registered.
3,399 studies on the registry are indexed under Stomach Neoplasms; 992 are open to participants now.
Browse Stomach Neoplasms studies →78 of the 521 studies in Stomach Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
SK Life Science, Inc. · Sites in Korea, Republic of, United States
Gyeongsang National University Hospital · Sites in Korea, Republic of
Dong-A ST Co., Ltd. · Sites in Korea, Republic of
Samsung Medical Center · Sites in Korea, Republic of
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 702 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 68 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
521 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 194 · Phase 3 96 · Phase 4 13
First in 2000; this study’s year is marked. 29 started in 2015.
This study's planned enrollment of 800 is above the median of 278 across 790 observational studies indexed under Stomach Neoplasms.
Median enrollment 95 across the 448 interventional studies, 444 across the 71 observational. Of the 301 that completed or were terminated, 59 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
182 of 521 have an industry lead sponsor. The 10 most frequent:
Kyungpook National University Hospital is the lead sponsor of 80 studies on the registry; 8 are open to participants now.
Kyungpook National University Hospital has 5 studies filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
27 of the studies in Stomach Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07488611Phase 3Soonchunhyang University HospitalPROGAIN Trial in Gastric Cancer Surgery | 2027-02 |
| NCT06532006Phase 3Shanghai Henlius BiotechA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | 2027-06-01 |
| NCT06219941AstraZenecaAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | 2026-11-17 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT05620628Jeeyun LeePh2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | 2026-12 |
Among the 521 studies in Stomach Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
discovery and validation of biomarker predicting gastric cancer chemotherapy response
discovery and validation of biomarker predicting gastric cancer chemotherapy response
Analysis for expression level of mRNA in fresh frozen gastric cancer tissue by chemotherapy response (A) method of mRNA expression measurement: RNA sequencing (B) study group Palliative chemotherapy (inoperable patients)
institutional primary Chemotherapy regimen (XP or Xelox)
progression group
Post-OP adjuvant chemotherapy
institutional primary Chemotherapy regimen
<!-- -->
Analysis for expression level of miRNA using Next generation sequencing in gastric cancer tissue and blood by chemotherapy response (A) method of mRNA expression measurement: RNA sequencing (B) study group
\<Next generation sequencing analysis> (A) palliative chemotherapy
(B) adjuvant chemotherpay
\<qRT-PCR analysis> (Experimental set) (A) palliative chemotherapy
(B) adjuvant chemotherpay
(Validation set) (A) palliative chemotherapy
(B) adjuvant chemotherpay
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
After initial chemotherapy, responder (complete remission, partial remission)
Drug: Chemotherapy
After initial chemotherapy, disease progression
Drug: Chemotherapy
complete cure and no recurrence at least 1 year after treatment
Drug: Chemotherapy
non-complete cure or recurrence within 1 year after treatment
Drug: Chemotherapy
Institutinal standard chemotherapy as first line : XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin
Also known as: XP or Xelox +/- Herceptin
Discovery of predicting bio-markers for gastric cancer chemotherapy response
Discovery of predicting bio-markers for gastric cancer chemotherapy response using next generation sequencing and qRT-PCR
Time frame: up to 36 months
Combination prediction model for adjuvant chemotherapy response in gastric cancer
Combination prediction model of biologic biomarkers and clinical factors for the response of adjuvant chemotherapy in gastric cancer
Time frame: up to 5 years
Combination prediction model for palliative chemotherapy response in gastric cancer
Combination prediction model of biologic biomarkers and clinical factors for the response of palliative chemotherapy in gastric cancer
Time frame: up to 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2015 (actual). Primary completion is estimated for Dec 2024, 109 months after the start.
Of 322 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 109 months is above that.
Counting every sponsor, half of 364 studies reached it within 54 months; a quarter within 29 and three quarters within 119.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kyungpook National University Hospital